Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGrainger plc Share News (GRI)

Share Price Information for Grainger plc (GRI)

Share Price is delayed by 15 minutes
Get Live Data
162.90    -2.20 (-1.33%)
Bid:
162.80
Ask:
163.10
Spread: 0.30 (0.184%)
Market Cap: £1.20b
GRI Live PriceLast checked at - London Stock Exchange

Intraday Grainger plc Share Chart

Grainger gets permission for Lambeth redevelopment

Fri, 20th Dec 2019 07:20
(Sharecast News) - Grainger said it had received planning permission to redevelop one of its housing estates in the London borough of Lambeth to supply 215 homes.
The project, close to Waterloo station, will increase the number of homes at the OCCC estate from 69, including 33 new homes for long-term protected tenants and 36 affordable homes. It will have new office space for local businesses and rehearsal space for the nearby Old Vic theatre.

The FTSE 250 company is Britain's biggest listed residential landlord. It has a pipeline of more than 4,500 new homes in London including over 3,000 in a joint venture with Transport for London.

Chief executive Helen Gordon said: "This [decision] is especially pleasing as it endorses Grainger's ability to recycle its property assets to not only provide a greater volume of new PRS [private rented sector] homes in London but to provide new housing for our current regulated tenancy residents in Waterloo.

"Looking ahead to 2020, Grainger's PRS pipeline and schemes to build circa 9,104 homes are continuing to gain momentum; regional city clusters are being increased and new PRS opportunities are forthcoming."

Related News

LONDON BRIEFING: Rathbones takes regulatory hit; boohoo narrows loss
2 days ago

LONDON BRIEFING: Rathbones takes regulatory hit; boohoo narrows loss

(Alliance News) - Rathbones flags a GBP60 million regulatory remediation charge, while International Workplace Group and Hilton Food Group unveil lead...

WINNERS & LOSERS: WH Smith seeks capital, cuts outlook; Workspace down
10 Jun 2026

WINNERS & LOSERS: WH Smith seeks capital, cuts outlook; Workspace down

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

LONDON BROKER RATINGS: Peel Hunt raises Babcock International to 'buy'
20 May 2026

LONDON BROKER RATINGS: Peel Hunt raises Babcock International to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Grainger plc News

Grainger Seeks GBP185 Million To Pursue New Investments
13 Feb 2020

Grainger Seeks GBP185 Million To Pursue New Investments

Grainger Seeks GBP185 Million To Pursue New Investments

Grainger Makes Encouraging Start To Year With Strong Rental Growth
5 Feb 2020

Grainger Makes Encouraging Start To Year With Strong Rental Growth

Grainger Makes Encouraging Start To Year With Strong Rental Growth

Grainger sees improved housing market as rental income grows
5 Feb 2020

Grainger sees improved housing market as rental income grows

(Sharecast News) - Private rental sector company Grainger said the recent UK General Election result had driven improved housing market sentiment as i...

UK Dividends Calendar - Next 7 Days
3 Feb 2020

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days
29 Jan 2020

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

UK BROKER RATINGS SUMMARY: Barclays Downgrades Glaxo To Underweight
16 Jan 2020

UK BROKER RATINGS SUMMARY: Barclays Downgrades Glaxo To Underweight

UK BROKER RATINGS SUMMARY: Barclays Downgrades Glaxo To Underweight

Grainger Gets Planning Consent To Redevelop Site Near Waterloo Station
20 Dec 2019

Grainger Gets Planning Consent To Redevelop Site Near Waterloo Station

Grainger Gets Planning Consent To Redevelop Site Near Waterloo Station

LONDON MARKET PRE-OPEN: AstraZeneca Sells Cancer Drug Rights
20 Dec 2019

LONDON MARKET PRE-OPEN: AstraZeneca Sells Cancer Drug Rights

LONDON MARKET PRE-OPEN: AstraZeneca Sells Cancer Drug Rights